Ad
Sunday, 2 June 2019
Lynparza stalls pancreatic cancer in patients with BRCA mutations: study
AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go longer without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment